Roche and SGX enter anti-viral partnership

Published: 22-Sep-2004

Roche and San-Diego-based SGX (Structural GenomiX) have formed an alliance to discover new anti-viral therapeutics.


Roche and San-Diego-based SGX (Structural GenomiX) have formed an alliance to discover new anti-viral therapeutics.

Using its proprietary FAST technology, SGX will be responsible for discovering small molecule inhibitors for Roche to develop and commercialise worldwide. SGX will receive an upfront payment, research funding and milestone payments as product candidates advance through development, and royalties on product sales.

'We seek partners that will help build our pipeline in areas of strategic focus,' said Peter Hug, Roche's global head of pharma partnering. 'SGX will be generating new anti-viral leads for Roche, further strengthening our commitment to developing novel medicines in virology.'

'This partnership with Roche is consistent with our integrated business strategy,' added Dr. Stephen Burley, SGX's chief scientific officer, 'which is to apply FAST to generate novel lead candidates in key therapeutic areas for strategic partners, as well as oncology candidates for further development by SGX.'

You may also like